Genetic Mechanisms and Therapeutic Strategies in Ovarian Cancer
A special issue of Genes (ISSN 2073-4425). This special issue belongs to the section "Human Genomics and Genetic Diseases".
Deadline for manuscript submissions: 25 June 2026 | Viewed by 27
Special Issue Editor
Special Issue Information
Dear Colleagues,
Epithelial ovarian cancer (EOC), which accounts for approximately 95% of all ovarian cancers, is the most lethal subtype with a poor prognosis of recurrence. Ovarian cancer is responsible for nearly 65% of all gynecologic cancer-related deaths. The 5-year survival rate is less than 30% and the tumor usually spreads to distant sites. Platinum-based chemotherapeutics remain the first-line treatment for ovarian cancer; however, a significant proportion of patients develop resistance to the treatment. Additionally, immunotherapeutic approaches have also failed in ovarian cancer due to metabolic, genomic, and immune perturbations in the tumor microenvironment.
Ovarian cancer is characterized by genetic and epigenetic alterations as well as changes in amplification of genes, copy number variations and single nucleotide variants. Epigenetic modifications including DNA methylation, histone modifications, non-coding RNAs, chromatin remodeling, and RNA methylation have been shown in ovarian cancer development, progression, and treatment resistance and offer a promising strategy for use in treatment.
In this Special Issue, we will report on the latest advances in the research and therapeutic intervention strategies to define the Genetic Mechanisms and Therapeutic Strategies in Ovarian Cancer.
Dr. Aimee Stablewski
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- epithelial ovarian cancer (EOC)
- genetic alterations
- epigenetic regulation
- tumor microenvironment
- therapeutic strategies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
